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Background: To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer
(advanced CRC) treated with oxaliplatin and fluoropyrimidines.
Methods: Tumor specimens from 201 patients with advanced CRC from a randomized, phase III trial comparing
oxaliplatin/5-FU vs. oxaliplatin/capecitabine were retrospectively analyzed for KRAS mutations. Mutation data were
correlated to response data (Overall response rate, ORR), progression-free survival (PFS) and overall survival (OS).
Results: 201 patients were analysed for KRAS mutation (61.2% males; mean age 64.2 ± 8.6 years). KRAS mutations
were identified in 36.3% of tumors (28.8% in codon 12, 7.4% in codon 13). The ORR in codon 13 patients compared
to codon 12 and wild type patients was significantly lower (p = 0.008). There was a tendency for a better overall
survival in KRAS wild type patients compared to mutants (p = 0.085). PFS in all patients was not different in the
three KRAS genetic groups (p = 0.72). However, we found a marked difference in PFS between patients with codon
12 and 13 mutant tumors treated with infusional 5-FU versus capecitabine based regimens.
Conclusions: Our data suggest that the type of KRAS mutation may be of clinical relevance under oxaliplatin
combination chemotherapies without the addition of monoclonal antibodies in particular when overall response
rates are important.
Trial registration number: 2002-04-017
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The oncogene KRAS belongs to the protein family of
small G-proteins and is mutated in 35-40% of colorectal
cancers (CRC) [1]. RAS mutations are considered early
events in colon carcinogenesis and are well conserved
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distribution, and reproduction in any medium[2]. KRAS mutations tested routinely include six muta-
tions in codon 12 and one mutation in codon 13.
KRAS has been studied extensively as a prognostic
marker in CRC, but results are still conflicting. Overall,
there seems a tendency towards inferior outcome for
patients with KRAS mutant tumors even in large rando-
mized trials [3-7]. Importantly, KRAS has recently been
identified as a strong predictive marker for patients with
advanced CRC under anti-EGFR-treatment. Various
studies demonstrated that while patients with tumors
expressing wild type KRAS may benefit from anti-EGFR
(epidermal growth factor receptor)-antibody treatment,d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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In contrast, two large trials using oxaliplatin-based
chemotherapy-backbones did not confirm KRAS wild
type to be a powerful predictor of treatment efficacy in
metastatic CRC [4,11]. However, the studies published
until recently did not differentiate between the different
KRAS mutations and other histopathological or molecu-
lar features of their patients. The clinical observation,
that some patients with KRAS mutation may respond to
anti-EGFR-antibody therapy, as well as experimental
data, that the biological effects of KRAS mutations may
differ, was addressed recently by de Roock and Tejpar
[12,13]. They reported that patients with codon 13
mutations in KRAS exhibit a worse overall prognosis
with short overall survival times under standard chemo-
therapy, but may benefit from anti-EGFR-antibody ther-
apy similar to wild type patients. These observations
prompted us to look for the effect of the KRAS muta-
tional status in correlation with response and survival
data in patients with advanced colorectal cancer receiv-
ing oxaliplatin containing chemotherapy from a pro-
spective randomized multicenter phase III trial of the
German AIO study group.Methods
Patients
All patients participated in a prospective randomized
phase III first-line palliative chemotherapy trial of
advanced CRC of the AIO colorectal study group
(Arbeitsgemeinschaft Internistische Onkologie of the
German Cancer Society). The study was performed
according to the Helsinki declaration and it was
approved by the ethics review board of the Central
Hospital Bremen and of the Medical Faculty of the
Ruhr-University Bochum. The study design, patient
characteristics, treatment plans and results of the clinical
trial have been reported previously [14]. Briefly, a total
of 474 patients were randomized to be treated with ei-
ther 5-FU/folinic acid (FA) and oxaliplatin (FUFOX: oxa-
liplatin, 50 mg/m2; FA, 500 mg/m2; continuous 5-FU,
2,000 mg/m2/22 h; on day 1, 8, 15, 22; q day 36) or cape-
citabine and oxaliplatin (CAPOX: oxaliplatin, 70 mg/m2
on day 1 and 8; capecitabine, 2 × 1,000 mg/m2/day con-
secutively for 2 weeks, q day 22). No clinical factor was
found to be predictive for definition of a subgroup of
patients benefiting more or less from each fluoropyrimi-
dine backbone. We here present data on a subcohort of
201 patients (42.4%) with available formalin-fixed paraf-
fin-embedded tissue. Samples were retrieved from
pathologists responsible for first diagnosis, pseudonony-
mized and forwarded to the Institute of Pathology of the
Ruhr-University Bochum, which was blinded to treat-
ment allocation and prognostic outcomes.DNA extraction and mutation analysis
DNA was extracted from anonymized formalin-fixed
paraffin embedded tissue samples. For each patient,
five 10-μm sections were prepared. An additional rep-
resentative 1-μm section was deparaffinized, stained
with H&E, and analyzed for detailed morphology.
Regions displaying tumor cellularity of >70% were
marked and macrodissected. Tissue was extracted
using QIAmp DNA Mini kit (Qiagen, Hilden, Ger-
many). Real-Time PCR amplification for the most fre-
quent seven KRAS mutations was performed using
commercially available kits from DxS Ltd. (Manchester,
UK) according to the manufacturer’s instructions. This
kit detects >95% of known KRAS mutations. Labora-
tory staff was blinded to the patient data and clinical
outcome. BRAF mutation analysis to detect the V600E
substitution was performed by RT-PCR (see supple-
mental file for further details).Statistical analysis
Chi-square test was used to evaluate the associations be-
tween KRAS status and other dichotomous variables.
The analysis of progression-free survival (PFS) and over-
all survival (OS) was done using the Kaplan-Meier
method and differences between subgroups were calcu-
lated by log-rank test. Data have been analyzed using
SPSS 18.0 (Munich, Germany). All tests were two sided.
For all tests, p values <0.05 were considered significant.Results
Patient characteristics
The subcohort of patients successfully analyzed for KRAS
mutations consisted of 201 patients (61.2% males with a
mean age of 64.2±8.6 years, range 35 – 82). Colon cancer
was diagnosed in 131 (65.2%) patients while rectal cancer
was diagnosed as primary tumor in 61 (30.3%) patients.
Localization was not known for 9 cases (4.5%). 105 (52.2%)
patients were treated with FUFOX, whereas 96 (47.7%)
patients received CAPOX. 115 (57.2%) patients had syn-
chronous metastases, whereas 59 (29.4%) had metachro-
nous metastases. Whether metastases were synchronous or
metachronous was not known for 27 ( 13.4%) patients
(Table 1). The subcohort reported here was representative
of the complete study cohort with respect to age, gender,
treatment plans (i.e. percentage of patients with FUFOX
and CAPOX respectively). Median PFS and OS of the total
ITT (intention-to-treat) population [14] and the biomarker
subpopulation were fully comparable (PFS under FUFOX
was 8.0 in the ITT cohort vs. 7.8 in the KRAS cohort; PFS
under CAPOX was 7.1 vs. 7.0; OS under FUFOX was 18.8
in the ITT cohort vs. 17.5 in the KRAS subcohort and OS
under CAPOX was 16.8 vs. 18.4).
Table 1 Baseline characteristics of the investigated
subcohort




≤60 y 58 28.9


























*M0 indicates metachronous metastatic disease at initial diagnosis of CRC, M1
indicates synchronous metastatic disease at initial diagnosis of CRC. n.k. = not
known – there were no data available.
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KRAS mutations could be successfully analyzed in 201
samples. We identified KRAS mutations in 73/201
(36.3%) tumors. 58 (28.9%) of KRAS mutations were
located in codon 12, whereas 15 (7.46%) were found in
codon 13(see Table 2). The three most frequent KRAS
alterations in our samples were c.35 G>A (G12D,
n = 25; 12.4%), c.38 G>A (G13D, n = 15; 7.46%), and
c.35 G>T (G12V, n = 13, 6.46%). In 128 patients no
KRAS mutation was found (63.6%). In these patients we
detected 13 mutations in the BRAF gene (V600E) (10%
of wild type patients).Correlation between mutations and response rate
Tumor response evaluation was available for 201
patients. Grouping all KRAS mutations together, mutated
tumors were associated with a significantly lower re-
sponse rate (RR; defined as partial or complete remission
by RECIST) as compared to tumors without KRAS muta-
tions (44.4% vs. 63.0%, p = 0.012). When patients with
codon 13 mutated tumors were analysed separately the
overall response rate in this cohort was 23% as compared
to 49% in codon 12 mutated tumors and 63% in wild type
tumors (Table 3, p = 0.008). Disease control rates (DCR)
were 77%, 81% and 88%, respectively, which was not sta-
tistically significant (Table 3, p = 0.29).
Correlation between mutations and progression-free
survival
During follow-up, 170 of 201 evaluable patients had pro-
gressed. The median PFS in all patients of the KRAS
subcohort was not statistically different in relation to the
KRAS mutational status (wild type: 7.5 months, muta-
tion codon 12: 8.2 months, mutation codon 13:
10.0 months; p = 0.71) (Figure 1). However, when analys-
ing the two treatment arms separately, we found a sub-
stantial, non-significant, difference in PFS in codon 13
mutated tumors versus codon 12 mutated tumors. While
median PFS was as low as 6.1 months for codon 13
patients receiving infusional 5-FU, median PFS was
13.3 months in patients treated with capecitabine (HR:
2.52, p = 0.22). Patients with codon 12 mutations showed
a trend towards the opposite effect: median PFS was
7.0 months under CAPOX therapy while median PFS
was 9.9 months under FUFOX (HR: 0.62, p = 0.12)
(Table 4).
Correlation between mutations and overall survival
During follow-up 135 of 201 evaluated patients had died.
We observed a trend towards a better survival time in
patients with wild type tumors compared to those with a
mutation of KRAS. The overall survival of wild type
KRAS patients was 19.2 months, for patients with codon
12 mutations 15.6 months and for patients with codon
13 mutations 16.5 months. These differences were of
marginal significance (p = 0.085) (Figure 2).
Evaluating the different treatment arms separately, we
found comparable survival times without significant dif-
ferences (Table 5). Since the survival curves seemed to
separate for wild type KRAS and mutant KRAS patients
at 14 months we hypothesised that this difference was
most likely caused by the influence of post-study treat-
ment. 71 out of 128 (55.4%) wild type patients received
further lines of therapy while 32 out of 128 wild type
patients (25%) received cetuximab. Out of 73 patients
with KRAS mutations 42 were treated in further lines
(57.5%) with 10 patients receiving cetuximab (13.7%).
Table 2 KRAS mutation frequency in the investigated









Aspartate (G12D) c.35G>A 12,4 25
Valine (G12V) c.35G>T 6,5 13
Alanine (G12A) c.35G>C 3,4 7
Cysteine (G12C) c.34G>T 3 6
Serine (G12S) c.34G>A 3 6
Arginine (G12R) c.34G>C 0,5 1
CODON 13 mutation:
Aspartate (G13D) c.38G>A 7,5 15
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patients receiving second and further line therapies,
patients receiving cetuximab had a significant better
overall survival when compared to those patients under
irinotecan therapy only, irrespective of the KRAS status.
PPS in KRAS wild type patients: 32.2 months when
cetuximab was given and 18.8 months when cetuximab
was not included (p < 0.001). PPS for KRAS mutant
patients: 27.9 months under cetuximab and 16.9 months
without cetuximab (p = 0.032).Discussion and conclusions
We assessed the prognostic value of KRAS codon 12
and codon 13 mutations in tumor tissue from patients
with advanced CRC recruited into a phase III clinical
trial using CAPOX or FUFOX treatment regimens. This
is the first randomized phase III trial retrospectively in-
vestigating the role of codon 13 mutations in advanced
CRC patients treated with oxaliplatin combination
chemotherapy only, without the addition of a monoclo-
nal antibody. While the overall response rate in codon
13 patients was significantly lower, PFS was not different
in the three KRAS mutational groups. Interestingly, we
found a substantial difference in PFS between patientsTable 3 Tumor response assessment and correlation to KRAS
All patients All WT Codo
No. of patients% 201 128
100 63.6
ORR% 55 63
95% CI (49–61) (54–71)
DCR% 85 88
95% CI (80–90) (80–92)
All patients. Percentages based on non-missing data, p-values for WT vs Codon 12
disease control rate.with codon 12 and 13 mutant tumors when looking at
infusional 5-FU versus capecitabine based regimens.
Patients with codon 13 mutations seem to benefit more
in terms of PFS from the oral capecitabine based proto-
cols. Moreover, there was a strong trend towards better
overall survival in patients with wild type KRAS com-
pared to all mutant KRAS patients. Lastly, when analys-
ing OS in patients who received second and further line
therapy we found that KRAS wild type and KRAS mu-
tant patients alike showed a significantly higher OS post
progression when treated with cetuximab.
A number of studies have looked at the potential prog-
nostic or predictive value of KRAS mutations on re-
sponse rates and survival in patients with CRC and
several studies found a negative impact of KRAS muta-
tions on prognosis [3,7,15-17].
Recently, a number of randomized trials have included
translational research programs to evaluate certain target
genes and their role as prognostic or predictive markers
in patients with metastatic disease. Thereby, the muta-
tional status of KRAS has now been established as a
strong predictive marker of resistance to anti-EGFR-
antibody treatment [5,8,10], although some trials could
not fully confirm these results [4,11]. We still do not
exactly know whether KRAS mutations influence the re-
sponse to other treatment regimens such as standard
chemotherapy or bevacizumab combinations. While bev-
acizumab efficacy seems independent from the KRAS
status [18], the activity of certain chemotherapeutic
agents may be influenced by KRAS mutations. There,
patients seem to do worse under oxaliplatin combina-
tions when carrying a mutant KRAS gene within their
primary cancer [4,5,7,16,19,20]. For example, in the re-
cently reported COIN study patients under oxaliplatin/
5-FU combinations showed a median PFS of 8.6 months
in the wild type KRAS cohort while median PFS was
only 6.9 months in the KRAS mutant cohort [4]. Simila-
rily, ORR was lower in KRAS mutant patients receiving
chemotherapy with oxaliplatin only (41% vs. 50%). Fur-
thermore, another recent small study evaluated the
KRAS status in 66 patients receiving a second line
chemotherapy with oxaliplatin and infusional 5-FUmutational status







mutations vs codon 13 mutations; WT wild type; ORR overall response rate, DCR
Figure 1 Progression-free survival according to KRAS status.
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This study found a significantly lower response rate (7%
vs. 27%, p = 0.026) and significantly shorter median PFS
(3.1 vs. 5.2 months, p = 0.007) for patients with mutant
KRAS tumors compared to patients with wild type KRAS
tumors under oxaliplatin containing therapy.
Very recently, experimental and some clinical reports
suggested that not all KRAS mutations behave alike
[12,13,21]. In fact, there is evidence that patients carry-
ing mutations in codon 13 of the KRAS oncogene which
is found in about 8% of patients with advanced CRC
have a substantially worse overall prognosis but may, on
the other hand, benefit from anti-EGFR-treatment.
In our study we found a similar rate of codon 13
mutations as described before. The overall response rate
in patients with codon 13 mutations in our analysis wasTable 4 PFS (progression free survival) according to KRAS
mutation for the two different treatment arms
PFS FUFOX CAPOX p-value (log rank)
n= 105 n= 96 HR (95% CI)
All patients 8.2 months 6.4 months 0.180.81 (0.61-1.09)










PFS, HR hazard ratio by cox regression, CI confidence interval, WT wild type.as low as 23%, significantly lower than in patients with
wild type or codon 12 mutations. The CRYSTAL- and
the OPUS-studies alike found low response rates in
patients with codon 13 mutations treated with combin-
ation chemotherapy only (17% for irinotecan combina-
tions and 33% for oxaliplatin combinations) [13]. In
contrast to previous reports, ORR was substantially
higher in this codon 13 mutant patient cohort when
cetuximab was added.
Our study was conducted using combination chemo-
therapy with oxaliplatin in first line treatment without
the addition of monoclonal antibodies. Interestingly, the
PFS and OS in our codon 13 cohort compared to the
other mutated groups and other previously published
works was rather long with a PFS of 10 months and an
OS of 16.5 months [13]. We do not know why PFS and
OS of the codon 13 cohort in our study was prolonged
when response rates were as low as 23%. Either low pa-
tient numbers or a yet unknown functional mechanism
of codon 13 mutated KRAS proteins within colon can-
cers may be responsible for the observation.
The present analysis also suggests that there may be
an interaction between the type of KRAS mutation and
the mode of application of 5-FU, i.e. whether adminis-
tered intravenously or orally as capecitabine. In particu-
lar, patients with codon 13 mutations showed longer
median PFS intervals when receiving capecitabine com-
pared to infusional 5-FU. Although the overall efficacy
of infusional 5-FU and capecitabine in advanced CRC
has been found to be comparable [22] there may be
Figure 2 Overall survival according to KRAS status.
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where the mode of application of the fluoropyrimidine is
more crucial. For example, anti-EGFR antibodies in wild
type KRAS patients may only be active when infusional
5-FU regimens are used, but not when capecitabine
based protocols are applied [4].
The potential resistance of KRAS mutated tumors to
oxaliplatin containing regimens seems interesting and
may reveal more general mechanisms of drug resistance
in cancers. Oxaliplatin belongs to the platinum contain-
ing compounds like cisplatinum and carboplatinum.
Metabolites of platinum compounds interact with DNA
and form crosslinks. In addition, platinum-DNA-adducts
strongly inhibit DNA polymerases and therefore act
antineoplastic. Some authors have studied in cell culture
systems and preclinical models the influence of onco-
genic RAS mutations on the activity of platinumTable 5 OS (overall survival) according to KRAS mutation
for the two different treatment arms
OS FUFOX CAPOX p-value (log rank)
n= 105 n= 96 HR (95% CI)
WT 24.2months 18.9months 0.31
0.79 (0.51-1.24)
Codon 12 15.6months 15.5months 0.54
mutation 0.83 (0.45-1.53)
Codon 13 16.1months 16.5months 0.62
mutation 1.39 (0.37-5.37)
OS, HR hazard ratio by cox regression, CI confidence interval.compounds and found that the nucleotide excision re-
pair protein ERCC-1 may be upregulated through acti-
vated RAS. ERCC-1 may subsequently activate DNA
repair capacity and thus mediate platinum resistance. A
recent study evaluated the role of ERCC-1 mRNA levels
in 191 patients treated with FOLFOX within the CON-
FIRM1 and CONFIRM2 studies. Low ERCC-1 gene ex-
pression was correlated with higher response rates to
FOLFOX chemotherapy and better overall survival. In
contrast patients with high ERCC-1 did not have benefit
from FOLFOX chemotherapy [23]. Of note, we have
examined the expression of ERCC-1 by immunohisto-
chemistry in our cohort and found no obvious correl-
ation with KRAS status, response rates or survival and
ERCC-1 expression (data not shown). The analysis of
the ERCC-1 expression levels by RT-PCR as reported by
other studies has not been performed so far [24].
Median overall survival after first progression corre-
lated with cetuximab-treatment in patients bearing
KRAS wild type and mutant tumors alike. The role of
codon 13 mutation in this setting appears minor since
there were only two patients with a codon 13 mutated
tumor in the cohort with KRAS mutations of whom we
know about cetuximab application. However, there are
at least two limitations to our analysis. First, numbers
are low in particular in the cetuximab group and sec-
ondly addition of cetuximab was not randomized for.
There seems to be a selection of patients with good per-
formance status and good prognosis who received third
line therapy compared to those who did not. Therefore,
Reinacher-Schick et al. BMC Cancer 2012, 12:349 Page 7 of 8
http://www.biomedcentral.com/1471-2407/12/349we can not draw definite conclusions from our analysis
whether anti-EGFR antibodies are effective in patients
with KRAS G13D mutations or not.
We presently can not draw final conclusions regarding
patient management from this study. It remains unclear
whether chemotherapy backbones with irinotecan are
less prone to interactions with mutated KRAS because
data regarding this issue are conflicting. Independent
validation of the findings is essential. Therefore, the
standardized, thorough and comprehensive collection of
tissue and blood samples of all trial patients within inde-
pendent cancer tissue banks should be a major goal of
modern clinical cancer trials.
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